• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.肠漏和肝脏:细菌易位在非酒精性脂肪性肝炎中的作用。
World J Gastroenterol. 2012 Jun 7;18(21):2609-18. doi: 10.3748/wjg.v18.i21.2609.
2
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.肠道微生物群和Toll样受体在非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381.
3
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.FXR 通过调节实验性肝硬化中细菌易位的进入部位来调节肠道-血管屏障。
J Hepatol. 2019 Dec;71(6):1126-1140. doi: 10.1016/j.jhep.2019.06.017. Epub 2019 Jul 8.
4
Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.非甾体抗炎药对肠道通透性和非酒精性脂肪性肝病的作用
World J Gastroenterol. 2017 Jun 14;23(22):3954-3963. doi: 10.3748/wjg.v23.i22.3954.
5
The role of the gut microbiota in nonalcoholic fatty liver disease.肠道微生物群在非酒精性脂肪性肝病中的作用。
Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):691-701. doi: 10.1038/nrgastro.2010.172. Epub 2010 Nov 2.
6
Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability.REV-ERBα 的药理学激活通过调节肠道通透性改善非酒精性脂肪性肝炎。
Metabolism. 2021 Jan;114:154409. doi: 10.1016/j.metabol.2020.154409. Epub 2020 Oct 21.
7
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.肠道微生物群驱动的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提。
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
8
The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.肠-肝轴在肝硬化和门静脉高压发病机制中的作用。
Clin Mol Hepatol. 2012 Dec;18(4):337-46. doi: 10.3350/cmh.2012.18.4.337. Epub 2012 Dec 21.
9
Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎中回肠-肝脏轴的固有免疫反应性。
Dig Dis Sci. 2012 May;57(5):1144-51. doi: 10.1007/s10620-012-2073-z. Epub 2012 Feb 25.
10
Gut-liver axis signaling in portal hypertension.门脉高压症中的肠道-肝脏轴信号。
World J Gastroenterol. 2019 Oct 21;25(39):5897-5917. doi: 10.3748/wjg.v25.i39.5897.

引用本文的文献

1
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.稳定的胃十五肽BPC 157作为治疗和安全关键:控制和调节血管生成及一氧化氮系统的特殊有益多效性作用
Pharmaceuticals (Basel). 2025 Jun 19;18(6):928. doi: 10.3390/ph18060928.
2
Gut feeling gone wrong: Tangled relationship between disorders of gut-brain interaction and liver disease.直觉出错:肠道-脑互动障碍与肝脏疾病之间的复杂关系
World J Hepatol. 2025 May 27;17(5):105582. doi: 10.4254/wjh.v17.i5.105582.
3
Gut dysbiosis mediates the association between antibiotic exposure and chronic disease.肠道微生物群失调介导了抗生素暴露与慢性病之间的关联。
Front Med (Lausanne). 2024 Nov 6;11:1477882. doi: 10.3389/fmed.2024.1477882. eCollection 2024.
4
Single and Mixed Strains of Probiotics Reduced Hepatic Fat Accumulation and Inflammation and Altered Gut Microbiome in a Nonalcoholic Steatohepatitis Rat Model.益生菌单菌株和混合菌株可减少非酒精性脂肪性肝炎大鼠模型中的肝脏脂肪堆积和炎症,并改变肠道微生物群。
Biomedicines. 2024 Aug 14;12(8):1847. doi: 10.3390/biomedicines12081847.
5
The Role and Mechanism of Metformin in Inflammatory Diseases.二甲双胍在炎症性疾病中的作用及机制
J Inflamm Res. 2023 Nov 23;16:5545-5564. doi: 10.2147/JIR.S436147. eCollection 2023.
6
Dysfunctional T Follicular Helper Cells Cause Intestinal and Hepatic Inflammation in NASH.功能失调的滤泡辅助性T细胞导致非酒精性脂肪性肝炎中的肠道和肝脏炎症。
bioRxiv. 2023 Oct 12:2023.06.07.544061. doi: 10.1101/2023.06.07.544061.
7
AflatoxinB (AFB ) and its toxic effect on the broilers intestine: A review.黄曲霉毒素 B(AFB)及其对肉鸡肠道的毒性作用:综述。
Vet Med Sci. 2023 Jul;9(4):1646-1655. doi: 10.1002/vms3.1169. Epub 2023 Jul 4.
8
The emerging role of the gut mycobiome in liver diseases.肠道真菌组在肝脏疾病中的新兴作用。
Gut Microbes. 2023 Jan-Dec;15(1):2211922. doi: 10.1080/19490976.2023.2211922.
9
Obesity and inflammation influence pharmacokinetic profiles of PEG-based nanoparticles.肥胖和炎症会影响基于 PEG 的纳米颗粒的药代动力学特征。
J Control Release. 2023 Mar;355:434-445. doi: 10.1016/j.jconrel.2023.02.007. Epub 2023 Feb 11.
10
A review of heat stress in chickens. Part I: Insights into physiology and gut health.鸡热应激综述。第一部分:生理与肠道健康洞察
Front Physiol. 2022 Aug 4;13:934381. doi: 10.3389/fphys.2022.934381. eCollection 2022.

本文引用的文献

1
Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH.口服 Imm124-E 可缓解胰岛素抵抗和肝损伤,其机制与增加 Tregs 有关,并与血清 GLP-1 和脂联素增加相关:NASH 的 I/II 期临床试验结果。
J Inflamm Res. 2012;5:141-50. doi: 10.2147/JIR.S35227. Epub 2012 Dec 20.
2
Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.肠道微生物群、肠道通透性、肥胖引起的炎症和肝损伤。
JPEN J Parenter Enteral Nutr. 2011 Sep;35(5 Suppl):14S-20S. doi: 10.1177/0148607111413772. Epub 2011 Aug 1.
3
Bacterial translocation is reduced by a specific nutritional combination in mice with chemotherapy-induced neutropenia.化疗诱导中性粒细胞减少症小鼠中,一种特定的营养组合可减少细菌易位。
J Nutr. 2011 Jul;141(7):1292-8. doi: 10.3945/jn.110.136986. Epub 2011 May 11.
4
Gut-liver axis and sensing microbes.肠-肝轴与感知微生物
Dig Dis. 2010;28(6):737-44. doi: 10.1159/000324281. Epub 2011 Apr 27.
5
Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice.肝特异性缺氧诱导因子-1α是小鼠酒精性脂肪变性中脂质积累和肝损伤的决定因素。
Hepatology. 2011 May;53(5):1526-37. doi: 10.1002/hep.24256.
6
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.脂肪酸和内毒素激活小鼠肝细胞中的炎性体,释放危险信号以刺激免疫细胞。
Hepatology. 2011 Jul;54(1):133-44. doi: 10.1002/hep.24341.
7
Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice.线粒体抗病毒信号蛋白缺陷导致小鼠脂肪性肝炎中抗病毒反应受损和肝损伤。
Hepatology. 2011 Jun;53(6):1917-31. doi: 10.1002/hep.24301. Epub 2011 May 2.
8
Antioxidant treatment attenuates intestinal mucosal damage and gut barrier dysfunction after major hepatectomy. Study in a porcine model.抗氧化治疗可减轻大鼠肝大部切除术后肠黏膜损伤和肠道屏障功能障碍。在猪模型中的研究。
J Gastrointest Surg. 2011 May;15(5):809-17. doi: 10.1007/s11605-011-1475-0. Epub 2011 Mar 5.
9
Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells.干扰素调节因子 3 和 I 型干扰素通过实质细胞和髓样细胞的串扰在小鼠酒精性肝损伤中起保护作用。
Hepatology. 2011 Feb;53(2):649-60. doi: 10.1002/hep.24059. Epub 2011 Jan 10.
10
Innate immunity in alcoholic liver disease.酒精性肝病中的固有免疫。
Am J Physiol Gastrointest Liver Physiol. 2011 Apr;300(4):G516-25. doi: 10.1152/ajpgi.00537.2010. Epub 2011 Jan 20.

肠漏和肝脏:细菌易位在非酒精性脂肪性肝炎中的作用。

Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.

机构信息

Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.

出版信息

World J Gastroenterol. 2012 Jun 7;18(21):2609-18. doi: 10.3748/wjg.v18.i21.2609.

DOI:10.3748/wjg.v18.i21.2609
PMID:22690069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3369997/
Abstract

Gut flora and bacterial translocation (BT) play important roles in the pathogenesis of chronic liver disease, including cirrhosis and its complications. Intestinal bacterial overgrowth and increased bacterial translocation of gut flora from the intestinal lumen predispose patients to bacterial infections, major complications and also play a role in the pathogenesis of chronic liver disorders. Levels of bacterial lipopolysaccharide, a component of gram-negative bacteria, are increased in the portal and/or systemic circulation in several types of chronic liver disease. Impaired gut epithelial integrity due to alterations in tight junction proteins may be the pathological mechanism underlying bacterial translocation. Preclinical and clinical studies over the last decade have suggested a role for BT in the pathogenesis of nonalcoholic steatohepatitis (NASH). Bacterial overgrowth, immune dysfunction, alteration of the luminal factors, and altered intestinal permeability are all involved in the pathogenesis of NASH and its complications. A better understanding of the cell-specific recognition and intracellular signaling events involved in sensing gut-derived microbes will help in the development of means to achieve an optimal balance in the gut-liver axis and ameliorate liver diseases. These may suggest new targets for potential therapeutic interventions for the treatment of NASH. Here, we review some of the mechanisms connecting BT and NASH and potential therapeutic developments.

摘要

肠道菌群和细菌易位(BT)在慢性肝病(包括肝硬化及其并发症)的发病机制中起着重要作用。肠道细菌过度生长和肠道菌群从肠腔向肠腔易位增加了患者发生细菌感染的风险,也是慢性肝脏疾病发病机制中的一个重要因素。几种类型的慢性肝病患者门静脉和/或全身循环中革兰氏阴性菌的组成成分细菌脂多糖的水平增加。由于紧密连接蛋白的改变,肠道上皮完整性受损,可能是细菌易位的病理机制。过去十年的临床前和临床研究表明,BT 在非酒精性脂肪性肝炎(NASH)的发病机制中起作用。细菌过度生长、免疫功能障碍、腔内容物因子的改变以及肠道通透性的改变都参与了 NASH 及其并发症的发病机制。更好地了解涉及肠道来源微生物的细胞特异性识别和细胞内信号事件将有助于实现肠道-肝脏轴的最佳平衡,并改善肝脏疾病。这些可能为 NASH 的治疗提供新的潜在治疗靶点。在这里,我们回顾了一些连接 BT 和 NASH 的机制以及潜在的治疗进展。